[ad_1]
The United States Food and Drug Administration (FDA) announced that the Covid-19 vaccine developed by Moderna was safe and 95 percent effective.
With this statement, the vaccine, which is said to be the way to get approval for emergency use, will be the second vaccine allowed in the US, if approved by the FDA Vaccine Panel.
In the US, the Pfizer-BioNTech vaccine was launched nationwide yesterday.
Unlike the Pfizer vaccine, Moderna’s vaccine does not need to be stored in very cold conditions during shipment.
Data on the Moderna vaccine was released ahead of the FDA meeting Thursday to consider the vaccine.
In the 54-page document, it was emphasized that the vaccine “was not a specific safety concern” and serious side effects were rare.
If Moderna vaccine is approved by FDA experts, it can be shipped within 24 hours.
According to the published document, an efficiency rate of 94.1 percent was achieved in the tests in 30 thousand people.
The most common side effects were listed as fever, headache, muscle and joint pain.
Founded in 2010, Moderna has never until now been able to develop an FDA-approved drug. The value of the company’s shares has risen 700 percent this year.
Differences from the Pfizer vaccine
Moderna vaccine should be kept at -20 degrees during shipping, at a temperature that normal freezers can provide.
Since Pfizer vaccine must be stored at -70 degrees, it can cause logistical problems.
Like the Pfizer vaccine, the Moderna vaccine must be given twice, with the second dose given 28 days after the first.
The company, based in Cambridge, Massachusetts, had announced that “the vast majority” of vaccines would be produced there if approved.
Pfizer’s vaccine is produced in different countries, including Germany and Belgium.
